ImmunologyJournal of Clinical InvestigationPeer-reviewed
Engineered NKG2C+ NK-like T cells exhibit superior antitumor efficacy while mitigating cytokine release syndrome
Kyle B. Lupo, M. Kazim Panjwani, Aya G. Halawi…·Katharine C. Hsu
This study shows that engineered NKG2C+ NK-like T cells have better antitumor effects and lower cytokine release syndrome risk than conventional CAR-T and CAR-NK cells.